Cosyntropin (Tetracosactide)
- Atc Codes:H01AA02
- CAS Codes:16960-16-0
- PHARMGKB ID:16960-16-0
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Dosage
- Pharmacokinetics and Pharmacodynamics
Brand Names
Europe
Austria: Synacthen; Belgium: Synacthen; Denmark: Synacthen; France: Synacthene; Germany: Synacthen; Greece: Nuvacthen Depot, Synacthene; Ireland: Synacthen; Italy: Synacthen; Luxembourg: Synacthen; Malta: Synacthen; Netherlands: Synacthen; Poland: Synacthen; Portugal: Synacthen Depot; Romania: Synacthen Depot; Spain: Nuvacthén Depot; Sweden: Synacthen; UK: Synacthen.
North America
Canada: Cortrosyn, Synacthen Depot; USA: Cortrosyn, Cosyntropin.
Latin America
Argentina: Synacthen.
Drug combinations
Chemistry
Cosyntropin: C~136~H~210~N~40~O~31~S. Mw: 2933.46. (1)α^1-24^-Corticotropin; (2)(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-1-[(2R)-2-[[(2R)-2-[[(2R)-6-amino-2-[[(2R)-6-amino-2-[[2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-amino-3-hydroxypropanoyl)amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-hydroxy-5-oxopentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-cyclohexylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]acetyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]acetyl]amino]hexanoyl]amino]hexanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carboxylic acid. CAS-16960-16-0 (1968).
Pharmacologic Category
Diagnostic Agents; Adrenocortical Insufficiency. (ATC-Code: H01AA02).
Mechanism of action
Stimulates the adrenal cortex to secrete adrenal steroids (including hydrocortisone, cortisone), androgenic substances, and a small amount of aldosterone.
Therapeutic use
Diagnostic test to differentiate primary adrenal from secondary (pituitary) adrenocortical insufficiency.
Pregnancy and lactiation implications
Unlabeled use
Contraindications
Hypersensitivity to cosyntropin or any component of the formulation.
Warnings and precautions
Use with caution in history of allergic reactions to corticotropin or pre-existing allergic disease.